Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA

Next Previous
X
Search
Trial Profile

Phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABL 103 (Primary) ; Pembrolizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ABL Bio

    • Most Recent Events

    • 11 Oct 2024 New trial record
    • 04 Oct 2024 According to ABL Bio media release, the company has entered into a clinical trial collaboration and supply agreement with MSD (a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), to evaluate ABL103 in combination with MSDs anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with advanced or metastatic solid tumors; Under the terms of the agreement, ABL Bio will conduct this trial and MSD will supply KEYTRUDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top